Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
PLoS One. 2012;7(12):e50750. doi: 10.1371/journal.pone.0050750. Epub 2012 Dec 7.
N-terminal fragments of mutant huntingtin (htt) that terminate between residues 90-115, termed cleavage product A or 1 (cp-A/1), form intracellular and intranuclear inclusion bodies in the brains of patients with Huntington's disease (HD). These fragments appear to be proteolytic products of the full-length protein. Here, we use an HEK293 cell culture model to investigate huntingtin proteolytic processing; previous studies of these cells have demonstrated cleavage of htt to cp-A/1 like htt fragments.
Recombinant N-terminal htt fragments, terminating at residue 171 (also referred to as cp-B/2 like), were efficiently cleaved to produce cp-A/1 whereas fragments representing endogenous caspase, calpain, and metalloproteinase cleavage products, terminating between residues 400-600, were inefficiently cleaved. Using cysteine-labeling techniques and antibody binding mapping, we localized the C-terminus of the cp-A/1 fragments produced by HEK293 cells to sequences minimally limited by cysteine 105 and an antibody epitope composed of residues 115-124. A combination of genetic and pharmacologic approaches to inhibit potential proteases, including γ-secretase and calpain, proved ineffective in preventing production of cp-A/1.
Our findings indicate that HEK293 cells express a protease that is capable of efficiently cleaving cp-B/2 like fragments of htt with normal or expanded glutamine repeats. For reasons that remain unclear, this protease cleaves longer htt fragments, with normal or expanded glutamine expansions, much less efficiently. The protease in HEK293 cells that is capable of generating a cp-A/1 like htt fragment may be a novel protease with a high preference for a cp-B/2-like htt fragment as substrate.
突变亨廷顿蛋白(htt)的 N 端片段在残基 90-115 之间终止,称为切割产物 A 或 1(cp-A/1),在亨廷顿病(HD)患者的大脑中形成细胞内和核内包涵体。这些片段似乎是全长蛋白的蛋白水解产物。在这里,我们使用 HEK293 细胞培养模型来研究亨廷顿蛋白的蛋白水解加工;先前对这些细胞的研究表明,htt 被切割成类似于 cp-A/1 的 htt 片段。
重组 N 端 htt 片段,在残基 171 处终止(也称为 cp-B/2 样),可有效地切割产生 cp-A/1,而代表内源性半胱天冬酶、钙蛋白酶和金属蛋白酶切割产物的片段,在残基 400-600 之间终止,切割效率较低。使用半胱氨酸标记技术和抗体结合图谱,我们将 HEK293 细胞产生的 cp-A/1 片段的 C 末端定位到最小限度地由半胱氨酸 105 和由残基 115-124 组成的抗体表位限制的序列。包括γ-分泌酶和钙蛋白酶在内的潜在蛋白酶的遗传和药理学抑制方法的组合在防止产生 cp-A/1 方面证明是无效的。
我们的发现表明,HEK293 细胞表达一种能够有效切割具有正常或扩展谷氨酰胺重复的 cp-B/2 样 htt 片段的蛋白酶。由于原因尚不清楚,这种蛋白酶切割具有正常或扩展谷氨酰胺扩展的更长 htt 片段的效率要低得多。能够产生 cp-A/1 样 htt 片段的 HEK293 细胞中的蛋白酶可能是一种新型蛋白酶,对 cp-B/2 样 htt 片段具有高偏好性作为底物。